[1] 江现强,俞渊,陆世锋,等. 腹腔镜肝叶切除术常见并发症的危险因素分析及临床处理. 实用肝脏病杂志,2017,20(2):215-218. [2] Sugawara Y,Inomata Y. Indications for living donor liver transplantation in patients with hepatocellular carcinoma. Hepatobiliary Surg Nutrit,2016,5:429-432.、 [3] 张跃伟. 微创介入治疗肝癌对机体免疫功能影响的研究现状与展望. 实用肝脏病杂志,2014,17(3):231-233,234. [4] Kalathil S,Lugade AA,Miller A,et al.Higher frequencies of GARP+ CTLA-4+ Foxp3+T regulatory cells and myeloid-derived suppressor cells in hepatocellular carcinoma patients are associated with impaired T cell functionality. Cancer Res,2013,73:2435-2444. [5] Yu SJ.A concise review of updated guidelines regarding the management of hepatocellular carcinoma around the world:2010-2016. Clin Mol Hepatol,2016,22:7-17. [6] Yau T,Tang VYF,Yao TJ,et al.Development of Hong Kong liver cancer staging system with treatment stratification for patients with hepatocellular carcinoma. Gastroenterology,2014,146:1691-1700. [7] Ju DY,Nakamura I,Roberts LR.The tumor microenvironment in hepatocellular carcinoma:Current status and therapeutic targets. Sem Cancer Biol,2011,21:35-43. [8] Shah DR,Green S,Elliot A,et al.Current oncologic applications of radiofrequency ablation therapies. World J Gastrointest Oncol,2013,5:71-80. [9] Yi Y,He HW,Wang JX,et al. The functional impairment of HCC-infiltrating γδ T cells,partially mediated by regulatory T cells in a TGFβ-and IL-10-dependent manner. J Hepatol,2013,58:977.、 [10] 吕永祥,郑伟. 腹腔镜肝切除联合微波消融治疗肝细胞癌患者疗效及安全性评价. 实用肝脏病杂志,2016,19(6):692-695. [11] Bang JS,Kim SH,Yang SH.Ileal perforation with diaphragmatic injury after radiofrequency ablation for hepatocellular carcinoma. Tur J Gastroenterol,2016,27:202. [12] Fuster J.Surgical treatment of hepatocellular carcinoma:should resection be performed according to Barcelona Clinic Liver Cancer Classification. Surg Today,2015,2(3):245-253. [13] Bacalbasa N,Balescu I,Tomescu D.Partial cystectomy with distal ureteral resection and re-implantation for locally invasive cervical cancer. Anticancer Res,2015,35(10):5539-5542. [14] Zhang Y,Huang F,Wang J,et al.MiR-15b mediates liver cancer cells proliferation through targeting BCL-2. Int J Clin Exp Pathol,2015,8(12):15677. [15] Mehta A,Herrera H,Block T.Chapter seven-glycosylation and liver cancer. Adv Cancer Res,2015,126:257-279. [16] Robertson CL, Srivastava J,Rajasekaran D,et al.The role of AEG-1 in the development of liver cancer. Hepat Oncol,2015,2(3):303. [17] Cho Y S,Shin M S,Ko I G,et al.Ulinastatin inhibits cerebral ischemia-induced apoptosis in the hippocampus of gerbils. Mol Med Rep NLM,2015,12(2):1796. [18] Prajapati HJ,Kim HS.Development of the new prognostic staging system(SS) in patients with unresectable hepatocellular carcinoma (HCC):multivariate survival analysis (MVA)-superior than Okuda,CLIP,BCLC,and Hong Kong Liver Cancer(HKLC) SSs. J Vasc Interv Radiol,2015,26(2):S66-S67. [19] Michele G,Chiara B.Non-coding RNAs in primary liver cancer. Front Med,2015,2(2):36. [20] Alakilli SYM,Mahrous KF.Evaluation of the chemopreventive impacts of lactoferrin on the initiation of liver cancer induced by diethylnitrosamine in male mice. IJPSRR,2015,32(2):59-66. [21] Yang B,Gao M,Wang K,et al.Intraintestinal administration of ulinastatin protects against sepsis by relieving intestinal damage. J Surg Res,2017,211(1):70-78. |